In short
This article explores the ongoing clinical trials of EO4010, a groundbreaking cancer vaccine therapy being tested in combination with other drugs for patients with previously treated metastatic colorectal cancer. The study aims to evaluate the safety, tolerability, and effectiveness of this innovative treatment approach in improving outcomes for patients with advanced colorectal cancer.
At a glance
- Study Drug
- EO4010 (novel microbial-derived peptide therapeutic vaccine)
- Combination Therapies
- Nivolumab and/or Bevacizumab
- Target Population
- HLA-A2 positive patients with previously treated metastatic colorectal cancer
- Primary Objective
- Evaluate safety and tolerability of EO4010 in combination with other drugs
- Secondary Objectives
- Assess immunogenicity, tumor response rates, progression-free survival, overall survival
- Study Design
- Global multicenter phase 1/2 trial with multiple cohorts
- Treatment Duration
- Expected to be completed by week 43, with follow-up visits
What is EO2317?
EO2317 is a new type of cancer treatment called a therapeutic vaccine. It is being studied as part of a combination therapy for patients with metastatic colorectal cancer who have already received other treatments. EO2317 is one of the active components in a vaccine called EO4010, which is being tested in clinical trials.
This vaccine is different from preventive vaccines that protect against diseases. Instead, EO2317 is designed to help treat cancer that has already developed and spread to other parts of the body.
How does EO2317 work?
EO2317 works by stimulating the body's immune system to fight cancer cells. It is a microbial-derived peptide, which means it's a small protein fragment derived from microorganisms. The vaccine is designed to: Help the immune system recognize and attack specific proteins (called tumor-associated antigens or TAAs) that are found on cancer cells Increase the number and activity of immune cells (specifically T cells) that can fight the cancer Work together with other cancer treatments to improve their effectiveness
Who is EO2317 for?
The current clinical trial is testing EO2317 (as part of the EO4010 vaccine) in patients with: Metastatic colorectal cancer: This means colorectal cancer that has spread from the colon or rectum to other parts of the body Cancer that cannot be surgically removed Cancer that has been previously treated with standard therapies A specific genetic profile (HLA-A2 positive) Patients must also meet other criteria, such as being at least 18 years old and having a good overall health status.
Clinical Trial Details
The clinical trial for EO2317 (as part of EO4010) is called the "AUDREY" study. It is a global, multicenter Phase 1/2 trial. Here are some key points about the trial: The vaccine is being tested in combination with other cancer treatments, including nivolumab (an immunotherapy drug) and bevacizumab (a drug that targets blood vessel growth in tumors) The trial is divided into different groups (cohorts) to test various combinations and doses of the treatments Patients receive regular scheduled visits to get the study treatment and undergo various tests and procedures The main goal is to evaluate the safety and effectiveness of the treatment combination
Potential Benefits
While it's important to note that the effectiveness of EO2317 is still being studied, the researchers hope to see benefits such as: Shrinking of tumors or slowing of tumor growth Longer time before the cancer progresses Improved overall survival A new treatment option for patients who have already tried standard therapies The study will measure these outcomes using various methods, including imaging scans and blood tests.
Safety and Side Effects
A primary goal of the clinical trial is to assess the safety of EO2317 when used in combination with other treatments. The researchers will carefully monitor patients for any side effects or adverse reactions. Common side effects of cancer vaccines may include: Injection site reactions (redness, swelling, or pain) Flu-like symptoms (fever, chills, fatigue) Nausea or vomiting It's important to note that as this is a new treatment, there may be unknown side effects. Patients in the trial will be closely monitored and should report any unusual symptoms to their healthcare team.